SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports that Nvidias board may remove Jensen Huang amid allegations involving workplace relationships and suspected Chinese intelligence links have dominated discussion, with traders debating leadership and governance risks while others dismiss the reports as unconfirmed and view the selloff as a buying opportunity. The boards reported deliberations and possible congressional scrutiny have intensified uncertainty around Huangs future, though no removal is confirmed.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Reports that Nvidias board may oust Jensen Huang amid misconduct and national-security scrutiny have fueled bets that customers and capital could shift toward AMD. Traders are divided over whether the move signals lasting market-share gains or is a sentiment-driven rally, arguing Nvidias leadership turmoil does not by itself change chip competitiveness.

GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

Reports and speculation that Nvidias board may oust CEO Jensen Huang are driving attention, with traders debating whether the controversy and related selloff are a buying opportunity or a sign of further downside. Many are buying the dip in NVDL ahead of Nvidia earnings, while noting that the ETFs 2 daily exposure can magnify moves in either direction.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

AMATs upcoming quarterly earnings report has traders focused on equipment orders and guidance as a read-through on whether AI-driven fab spending is holding up. The community is split between optimism about chipmaking demand and concern that capex could slow, with recent price strength prompting both rebound hopes and caution about the outlook.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos upcoming earnings report has traders focused on whether AI infrastructure orders will translate into durable revenue and cash flow, or reflect hyperscalers potentially lumpy data-center spending. Optimists point to strong networking demand, while skeptics highlight margin and inventory risks and question whether the order momentum is sustainable.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs quarterly results highlighted rapid growth in its Quake AI infrastructure business and a first positive adjusted EBITDA quarter, fueling a sharp rally. Traders are debating whether high short interest could amplify the move, while others point to the softer next-quarter outlook and uncertainty around financing further data-center expansion.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Strong Q3 growth led by Recorlev and raised revenue expectations, including an accelerated long-term sales outlook, are driving bullish discussion around Xeriss earnings-based rerating. Some traders also speculate about a buyout, but that remains unconfirmed, while others warn the sharp rally could pull back.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally is centered on the FDAs November 22 decision on deramiocel for Duchenne muscular dystrophy, with managements confidence in the trial data and comments about possible labeling fueling optimism. Traders are also discussing analyst upgrades and a potential short squeeze, while others stress that approval remains uncertain given prior FDA concerns and the binary nature of the decision.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMHs rebound is drawing attention as traders point to CoreWeaves upbeat outlook as support for AI-chip demand, while reported uncertainty around Nvidia CEO Jensen Huang and doubts about debt-funded AI spending keep some traders cautious. Others see the move as a buying opportunity, with chip stocks rebounding despite Nvidia-specific pressure.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

China-related security allegations and congressional scrutiny are a major focus, with traders debating whether the resulting pressure is overdone or signals lasting risk. Attention is also building around Webulls upcoming quarterly results: bulls cite growth and profitability and expect a recovery, while skeptics point to weak trading and persistent selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonPR NewswireRANCHO CUCAMONGA, Calif., Nov. 11, 2026 RANCHO CUCAMONGA, Calif., Nov. 11, 2026 /PRNewswire...

Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +46.15% and +6.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026PR NewswireRANCHO CUCAMONGA, Calif., Nov. 5, 2026 Net revenues of $207.6 million for the three months...

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of +30.00% and +19.08%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026 Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026PR NewswireRANCHO CUCAMONGA, Calif., October 29, 2026 RANCHO CUCAMONGA, Calif., October...

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of +63.89% and +7.11%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference PR Newswire RANCHO CUCAMONGA, Calif., Sept. 1, 2026 RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar...

• Reported GAAP EPS of $1.14 up 22.58% YoY
• Reported revenue of $207.61M up 8.22% YoY

Amphastar's gross margin was 48.0% versus 51.4%; IMS remediation was associated with slower product releases and decreased sales of several products, while increased competition lowered glucagon's average selling price.

Amphastar recorded record BAQSIMI and Primatene MIST sales, included contributions from recently launched products, and reported filed and developing pipeline candidates targeting markets exceeding $1.6B, $3.5B, and $1.2B.

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. It operates through Pharmaceutical Products segment. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Amphastar Pharmaceuticals Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.79	--	--	N/A
Q3 '26	$0.86	$1.14	32.77%	BEAT
Q2 '26	$0.62	$0.91	46.75%	BEAT
Q1 '26	$0.71	$0.42	-40.44%	MISSED
Q4 '25	$0.92	$0.73	-20.89%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMPH Earnings

Latest Earnings Results: Q3 '26

Historical Earnings